Principal Financial Group Inc. Has $204,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Principal Financial Group Inc. boosted its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 456.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 102,651 shares of the biotechnology company’s stock after buying an additional 84,205 shares during the period. Principal Financial Group Inc. owned about 0.07% of Heron Therapeutics worth $204,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. nVerses Capital LLC acquired a new stake in shares of Heron Therapeutics during the 2nd quarter valued at about $27,000. HB Wealth Management LLC acquired a new position in Heron Therapeutics in the second quarter worth about $35,000. Cutter & CO Brokerage Inc. bought a new position in Heron Therapeutics during the third quarter worth about $39,000. B. Riley Wealth Advisors Inc. acquired a new stake in Heron Therapeutics during the second quarter valued at approximately $41,000. Finally, Sei Investments Co. bought a new stake in shares of Heron Therapeutics in the 2nd quarter valued at approximately $44,000. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Stock Performance

Shares of HRTX stock opened at $1.14 on Tuesday. Heron Therapeutics, Inc. has a 52 week low of $1.04 and a 52 week high of $3.93. The stock has a market capitalization of $173.39 million, a PE ratio of -6.33 and a beta of 1.81. The stock’s fifty day moving average is $1.74 and its 200-day moving average is $2.44.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). The company had revenue of $32.81 million for the quarter, compared to the consensus estimate of $36.40 million. During the same period in the prior year, the company earned ($0.17) EPS. As a group, analysts forecast that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

HRTX has been the subject of several analyst reports. StockNews.com downgraded Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Needham & Company LLC cut their price objective on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a report on Wednesday, November 13th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.